CogniMIR™
Early detection of Mild Cognitive Impairment and Alzheimer's Disease
Pre-clinicalActive
Key Facts
Indication
Early detection of Mild Cognitive Impairment and Alzheimer's Disease
Phase
Pre-clinical
Status
Active
Company
About DiamiR
DiamiR is a private, pre-revenue diagnostics company pioneering a platform based on brain-enriched microRNA biomarkers detectable in blood plasma. Its lead program, CogniMIR™, targets the early detection of mild cognitive impairment and Alzheimer's disease, with additional programs in neurodevelopmental disorders and healthy aging. The company aims to address critical unmet needs in screening, differential diagnosis, and therapy monitoring through collaborations with academia and industry, supported by a growing intellectual property portfolio.
View full company profile